Cantor Fitzgerald Weighs in on Novavax FY2025 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Novavax in a report issued on Friday, October 24th. Cantor Fitzgerald analyst P. Stavropoulos expects that the biopharmaceutical company will post earnings of $2.23 per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $18.00 price target on the stock. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.69. The firm had revenue of $239.24 million for the quarter, compared to analyst estimates of $149.19 million. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.Novavax’s quarterly revenue was down 42.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.99 earnings per share.

NVAX has been the topic of several other reports. Bank of America reissued an “underperform” rating and set a $7.00 price target (down from $9.00) on shares of Novavax in a research report on Wednesday, August 20th. HC Wainwright upped their price target on Novavax from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Novavax in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $11.33.

Novavax Stock Up 2.1%

NASDAQ:NVAX opened at $8.70 on Monday. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of 3.82, a PEG ratio of 0.13 and a beta of 2.74. Novavax has a 1-year low of $5.01 and a 1-year high of $11.55. The company has a current ratio of 2.36, a quick ratio of 2.34 and a debt-to-equity ratio of 5.93. The business’s fifty day moving average price is $8.38 and its 200 day moving average price is $7.46.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Shah Capital Management grew its stake in Novavax by 3.4% in the second quarter. Shah Capital Management now owns 11,511,780 shares of the biopharmaceutical company’s stock valued at $72,524,000 after purchasing an additional 379,934 shares in the last quarter. Park West Asset Management LLC bought a new stake in shares of Novavax during the 1st quarter worth about $16,210,000. TSP Capital Management Group LLC boosted its stake in shares of Novavax by 3.5% during the 2nd quarter. TSP Capital Management Group LLC now owns 1,399,065 shares of the biopharmaceutical company’s stock worth $8,814,000 after acquiring an additional 46,900 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Novavax by 1.8% during the 3rd quarter. SG Americas Securities LLC now owns 918,683 shares of the biopharmaceutical company’s stock worth $7,965,000 after acquiring an additional 15,997 shares in the last quarter. Finally, Jupiter Asset Management Ltd. boosted its stake in shares of Novavax by 195.9% during the 2nd quarter. Jupiter Asset Management Ltd. now owns 880,410 shares of the biopharmaceutical company’s stock worth $5,547,000 after acquiring an additional 582,858 shares in the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.